The WinSport Canada facility operates under the scope of Hockey Canada, the national body regulating the sport across Canada. Located in Calgary's Canada Olympic Park, the 500,000-square-foot structure currently includes three North American-size ice rinks designed for hockey, sledge hockey as well as figure skaters. The facility has already been dubbed a calling card for Calgary in continuing to attract world-class athletes to the city.
With this shipment, scheduled for delivery upon completion of the facility, UV Flu will become an official supplier to Hockey Canada, and will continue to build brand awareness within the sport by directly introducing the product to the athletes who will benefit the most by its use. Hockey Canada will be an excellent addition to the growing list of teams and facilities utilizing the product including the Boston Bruins, Pittsburgh Penguins, and several notable college organizations.
"We believe we have not even scratched the surface for the potential demand of this product in the professional and college athletic marketplace," commented Charles Gulteri, President of NESSI. "Hockey and basketball are major sports where every player is critical to the team and the constant travel and changing weather conditions during cold and flu season create fertile conditions for the spread of illness. The UV-400 will prevent the spread of many of these airborne illnesses for an incredibly low price and we believe teams cannot afford to be without them in their team areas. We plan on talking with the NHL, as well as college teams, to further educate them on the importance of this product," said Mr. Gulteri.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp